|
|
|
||
(State or other jurisdiction of
incorporation)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
|
|
|
VIVEVE MEDICAL, INC.
|
|||
By:
|
/s/ Scott Durbin
|
||
Name:
|
Scott Durbin
|
||
Title:
|
Chief Executive Officer
|
Date:
|
November 23, 2022
|
Document And Entity Information |
Nov. 18, 2022 |
---|---|
Document Information [Line Items] | |
Entity, Registrant Name | VIVEVE MEDICAL, INC. |
Document, Type | 8-K |
Document, Period End Date | Nov. 18, 2022 |
Entity, Incorporation, State or Country Code | DE |
Entity, File Number | 1-11388 |
Entity, Tax Identification Number | 04-3153858 |
Entity, Address, Address Line One | 345 Inverness Drive South, Building B, Suite 250 |
Entity, Address, City or Town | Englewood |
Entity, Address, State or Province | CO |
Entity, Address, Postal Zip Code | 80112 |
City Area Code | 720 |
Local Phone Number | 696-8100 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock |
Trading Symbol | VIVE |
Security Exchange Name | NASDAQ |
Entity, Emerging Growth Company | false |
Amendment Flag | false |
Entity, Central Index Key | 0000879682 |
*HZ;ENMQDS(9U!+[\WTX.>RDPD))]IDF9QS/3N MGD=JVW>H<[SQ*M8;8V\T![V$K?FH8.7<^]?E%..F6GE9;HFUK4+,G M^5#SW@ GI)V5N='P5$ _,QBK((,@&S*4(9E((\R.3.5^MB%JO::!E]BFS> @ M>+\7],X(/JN/:T+]!O%XDWP;7IR3NQ0EDJ]VXMIV'=<2\0C'A@KP>#PP4<\BJP2
-8?20$3;8T.P6BP^0"X99K>]9!:G
(>>=DV[[
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MTMUD[ ;C-(,-[\J:=;'R;'?^ :6RR?13[C'H %X_UX(TPZ[4ZV\,?DP^FB
M:Q)&1VEVS.U2U:K8M4J]=@>&PT_E,C(\QPMCT9XR7(S_ HC[0O(GA'W"Y3HP
M#,:QBWY2G'C2L>Q_1W5^:;)H!],I%P)9CW9.M.K]E3C0+?0+@P+I3&=>L&3A
MLZA?VOQ)+RAD2,!8^#OXJ6.$H@IBGC+8_@M%3>5JX?!U+!_'KALR(